Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for ERAD and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RNF5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | RNF5 Full-Length Recombinant Protein HEK293 Expressed, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW ~34 kDa. |
View RNF5 Products |
| Antigen (Domain) | RNF5 RING Finger Domain (aa 1-73) Critical for E3 ligase activity and ubiquitin transfer. Sequence Verified. |
View RNF5 Products |
| Gene Delivery | RNF5 Promise-ORF / Lentivirus Full-length ORF with FLAG/HA tags for stable cell line construction. High titer (>10^8 TU/mL). |
View RNF5 Products |
| Validator | RNF5 siRNA Set (3 unique sequences) For knockdown and specificity verification in ubiquitination assays. Sequence Verified. |
View RNF5 Products |
| E2 Partner | UBE2G2 (Ube2g2) Primary E2 conjugating enzyme interacting with RNF5 for ERAD substrate ubiquitination. |
View UBE2G2 Products |
| Related E3 Ligase | RNF185 Paralog sharing ERAD functions; critical for counter-screening and selectivity profiling. |
View RNF185 Products |
| ERAD Complex | VCP/p97 AAA+ ATPase essential for RNF5-mediated extraction of ubiquitinated substrates from ER. |
View VCP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E3 Ligase Activity Validation (Auto-ubiquitination) | High-purity RNF5 RING Domain (>95%) with verified cysteine coordination; suitable for thioester assays. |
| PROTAC Ternary Complex Formation | Full-length RNF5 with native conformation; available with biotin/fluorophore conjugation for SPR/FRET. |
| Substrate Specificity (ERAD vs non-ERAD) | Matched UBE2G2 and VCP proteins available for reconstituted ubiquitination cascades. |
| Selectivity vs RNF Paralogs | RNF185 and RNF213 homolog proteins strictly verified by mass spec for counter-screening. |
| Cellular Localization Studies | Lentivirus particles with CMV promoter for stable overexpression in HeLa/HEK293 cells; ER retention signal preserved. |
Live RNF5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RNF5-targeted therapeutics is intensifying, with major players shifting focus from traditional protein degradation inhibitors to novel PROTAC recruiters exploiting RNF5's unique ERAD positioning. As first-generation ERAD modulators reach preclinical milestones, the next wave of R&D is targeting combination immunotherapies and neurodegenerative proteinopathies where RNF5-mediated proteostasis plays a critical regulatory role.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Emerging biotech (ERAD-focused) | Solid Tumors, Viral Infections | Auto-ubiquitination inhibition assay (Need purified RING domain with intact Zn-binding sites) |
| PROTACs (RNF5 as E3) | Academic labs, Biotech | Undruggable Kinases, Immunology | Ternary complex stability (Need full-length RNF5 with native membrane association) |
| Gene Silencing | siRNA therapeutic developers | Fibrosis, ER Stress Disorders | Knockdown efficiency validation (Need validated siRNA controls and qPCR standards) |
| Molecular Glues | Targeted protein degradation companies | Oncology | Substrate receptor competition assays (Need high-concentration RNF5 proteins) |